As of March 1, 2024, McKesson has acquired USRetina's GPO business assets. With this change, customers can expect enhanced, differentiated economics, streamlined processes, and greater physician alignment and engagement in the retina community.
Learn more about McKesson's retina solutions here.

Biosimilars in Focus for Retina Practices

Please join us on April 26, 2023 | 6:00 p.m. CT

More retina biosimilars are entering the pipeline, including last year’s first interchangeable product across all five indications. Don’t miss this upcoming opportunity to join our retina-focused discussion on Wednesday, April 26 to gain a better understanding of the foundational science behind biosimilars and the evolving payer landscape.

Hear from clinical and business experts:

Tim Ho, PharmD, BCOP
Regional Clinical Consultant, McKesson

Christine Kern, MBA
Regional Director Managed Care Contracting, McKesson

Key takeaways:

  • Understand the difference between reference drugs and biosimilars as well as the FDA’s position and guidelines
  • Learn about the clinical efficacy of biosimilar therapies
  • Address reimbursement hurdles
  • Learn how to develop a payer strategy
  • Prepare for biosimilars at your retina practice with confidence